An assessment by the Statin cognitive safety task force: 2014 update

Carlos H. Rojas-Fernandez; Larry B. Goldstein; Allan I. Levey; Beth A. Taylor; Vera Bittner

doi:10.1016/j.jacl.2014.02.013

An assessment by the Statin cognitive safety task force: 2014 update

Carlos H. Rojas-Fernandez, Larry B. Goldstein, Allan I. Levey, Beth A. Taylor, Vera Bittner

Research output: Contribution to journal › Article › peer-review

86 Scopus citations

Abstract

The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors.

Original language	English
Pages (from-to)	S5-S16
Journal	Journal of Clinical Lipidology
Volume	8
Issue number	3 SUPPL
DOIs	https://doi.org/10.1016/j.jacl.2014.02.013
State	Published - 2014

Bibliographical note

Funding Information:
Disclosures: The authors disclose that they have the following relationships with industry that might pose a potential conflict of interest(s): Dr Carlos Rojas-Fernandez (research grant support from Astra Zeneca, Pfizer, Bristol Myers Squibb, Medisystems Pharmacy, and Remedy's Rx Pharmacies ); Dr Allan Levey (research grant support from NIH [ P50 AG025688 ], Merck, Eli Lilly, Lundbeck, and Neurovision ; and consultant for Genomind and Genentech); Dr Larry Goldstein (past consultant for Pfizer and speaker at Pfizer-sponsored meetings); Dr Beth Taylor (honoraria - Pharmacovigilance Advisory Board Amgen, Inc.); and Dr Vera Bittner (research support from Amgen, Bayer Healthcare, Glaxo-Smith-Kline, Pfizer, Roche, and Sanofi Aventis ; and consultant for Amarin, Novartis, and the Federal Drug Administration).

Funding

Disclosures: The authors disclose that they have the following relationships with industry that might pose a potential conflict of interest(s): Dr Carlos Rojas-Fernandez (research grant support from Astra Zeneca, Pfizer, Bristol Myers Squibb, Medisystems Pharmacy, and Remedy's Rx Pharmacies ); Dr Allan Levey (research grant support from NIH [ P50 AG025688 ], Merck, Eli Lilly, Lundbeck, and Neurovision ; and consultant for Genomind and Genentech); Dr Larry Goldstein (past consultant for Pfizer and speaker at Pfizer-sponsored meetings); Dr Beth Taylor (honoraria - Pharmacovigilance Advisory Board Amgen, Inc.); and Dr Vera Bittner (research support from Amgen, Bayer Healthcare, Glaxo-Smith-Kline, Pfizer, Roche, and Sanofi Aventis ; and consultant for Amarin, Novartis, and the Federal Drug Administration).

Funders	Funder number
Dr Carlos Rojas-Fernandez
Federal Drug Administration
Glaxo Smith Kline
Medisystems Pharmacy
National Institutes of Health (NIH)	P50 AG025688
National Institutes of Health (NIH)
AMGen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Merck
Roche Diagnostics
Sanofi
Bayer HealthCare Pharmaceuticals Inc.
H. Lundbeck A/S

Keywords

Adverse drug effects
Cognition
Iatrogenesis
Memory
Statins

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Nutrition and Dietetics
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jacl.2014.02.013

Cite this

@article{e702b4a4979b498082772a1c3d2b7d71,

title = "An assessment by the Statin cognitive safety task force: 2014 update",

abstract = "The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors.",

keywords = "Adverse drug effects, Cognition, Iatrogenesis, Memory, Statins",

author = "Rojas-Fernandez, {Carlos H.} and Goldstein, {Larry B.} and Levey, {Allan I.} and Taylor, {Beth A.} and Vera Bittner",

note = "Funding Information: Disclosures: The authors disclose that they have the following relationships with industry that might pose a potential conflict of interest(s): Dr Carlos Rojas-Fernandez (research grant support from Astra Zeneca, Pfizer, Bristol Myers Squibb, Medisystems Pharmacy, and Remedy's Rx Pharmacies ); Dr Allan Levey (research grant support from NIH [ P50 AG025688 ], Merck, Eli Lilly, Lundbeck, and Neurovision ; and consultant for Genomind and Genentech); Dr Larry Goldstein (past consultant for Pfizer and speaker at Pfizer-sponsored meetings); Dr Beth Taylor (honoraria - Pharmacovigilance Advisory Board Amgen, Inc.); and Dr Vera Bittner (research support from Amgen, Bayer Healthcare, Glaxo-Smith-Kline, Pfizer, Roche, and Sanofi Aventis ; and consultant for Amarin, Novartis, and the Federal Drug Administration). ",

year = "2014",

doi = "10.1016/j.jacl.2014.02.013",

language = "English",

volume = "8",

pages = "S5--S16",

number = "3 SUPPL",

}

TY - JOUR

T1 - An assessment by the Statin cognitive safety task force

T2 - 2014 update

AU - Rojas-Fernandez, Carlos H.

AU - Goldstein, Larry B.

AU - Levey, Allan I.

AU - Taylor, Beth A.

AU - Bittner, Vera

N1 - Funding Information: Disclosures: The authors disclose that they have the following relationships with industry that might pose a potential conflict of interest(s): Dr Carlos Rojas-Fernandez (research grant support from Astra Zeneca, Pfizer, Bristol Myers Squibb, Medisystems Pharmacy, and Remedy's Rx Pharmacies ); Dr Allan Levey (research grant support from NIH [ P50 AG025688 ], Merck, Eli Lilly, Lundbeck, and Neurovision ; and consultant for Genomind and Genentech); Dr Larry Goldstein (past consultant for Pfizer and speaker at Pfizer-sponsored meetings); Dr Beth Taylor (honoraria - Pharmacovigilance Advisory Board Amgen, Inc.); and Dr Vera Bittner (research support from Amgen, Bayer Healthcare, Glaxo-Smith-Kline, Pfizer, Roche, and Sanofi Aventis ; and consultant for Amarin, Novartis, and the Federal Drug Administration).

PY - 2014

Y1 - 2014

N2 - The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors.

AB - The National Lipid Association's Safety Task Force convened a consensus conference of experts to develop a position statement on cognitive function to revise and update that published originally by the Association in the 2006 assessment of statin safety by a panel of neurologists. The current expert panel was charged with addressing the specific issue of potential adverse cognitive effects attributable to statins. Search strategies recently used in systematic reviews were used to identify relevant evidence using keywords and topics via Medline searches from 1966 to December 2013. Manual searches of bibliographies were also conducted. Panel members were asked to use the evidence to formulate answers to a series of questions of relevance to the subject matter. The strength of recommendations and quality of evidence were graded using accepted contemporary definitions and procedures. Recommendations to patients, health professionals, and researchers were put forth by the panel to aid in daily clinical decision making, and in future research endeavors.

KW - Adverse drug effects

KW - Cognition

KW - Iatrogenesis

KW - Memory

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84899874858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899874858&partnerID=8YFLogxK

U2 - 10.1016/j.jacl.2014.02.013

DO - 10.1016/j.jacl.2014.02.013

M3 - Article

C2 - 24793442

AN - SCOPUS:84899874858

SN - 1933-2874

VL - 8

SP - S5-S16

JO - Journal of Clinical Lipidology

JF - Journal of Clinical Lipidology

IS - 3 SUPPL

ER -

An assessment by the Statin cognitive safety task force: 2014 update

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this